Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial

M. Ladetto, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, V. Callea, C. Patti, P. Coser, A. Perrotti, M. Sorio, C. Boccomini, A. Pulsoni, C. Stelitano, R. Scimè, M. Boccadoro, R. Rosato, F. De Marco, M. Zanni, P. Corradini, C. Tarella

Research output: Contribution to journalArticlepeer-review

Abstract

This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiation-free, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninety-two untreated FL patients aged ≤60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected long-term progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy.

Original languageEnglish
Pages (from-to)1840-1847
Number of pages8
JournalLeukemia
Volume20
Issue number10
DOIs
Publication statusPublished - Oct 2006

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial'. Together they form a unique fingerprint.

Cite this